Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo Trio
NCT02858921Phase 2Active, not recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Nov 2017
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dabrafenib + trametinib, trametinib and pembrolizumab in melanoma (3 arms), sponsored by Melanoma Institute Australia. Primary endpoint: Pathological Response Rate at 6 weeks. Started Nov 2017; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02858921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858921.